STERIS plc (NYSE:STE – Get Free Report) has earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $283.50.
A number of research firms have recently weighed in on STE. Piper Sandler reaffirmed an “overweight” rating and issued a $275.00 price target (up from $270.00) on shares of STERIS in a research note on Friday, August 7th. Jefferies Financial Group upgraded STERIS from a “hold” rating to a “buy” rating and increased their price objective for the stock from $232.00 to $305.00 in a report on Friday, November 13th. Morgan Stanley raised STERIS from an “overweight” rating to a “buy” rating in a research report on Friday, November 13th. UBS Group lowered their target price on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Weiss Ratings raised STERIS from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, November 9th.
View Our Latest Research Report on STE
STERIS Stock Performance
STE stock opened at $254.93 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.44 and a current ratio of 2.05. The stock has a market cap of $24.76 billion, a P/E ratio of 30.24 and a beta of 0.86. The firm has a 50 day simple moving average of $226.54 and a 200 day simple moving average of $224.53. STERIS has a 52 week low of $195.14 and a 52 week high of $269.44.
STERIS (NYSE:STE – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $2.94 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.26. STERIS had a net margin of 13.41% and a return on equity of 14.80%. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the prior year, the business earned $2.47 EPS. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. Research analysts anticipate that STERIS will post 11.46 earnings per share for the current fiscal year.
STERIS Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Tuesday, November 17th will be paid a $0.69 dividend. The ex-dividend date of this dividend is Tuesday, November 17th. This represents a $2.76 annualized dividend and a dividend yield of 1.1%. STERIS’s payout ratio is presently 32.74%.
Insider Buying and Selling
In other STERIS news, CFO Karen L. Burton sold 5,880 shares of STERIS stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $255.62, for a total value of $1,503,045.60. Following the completion of the sale, the chief financial officer directly owned 12,956 shares in the company, valued at $3,311,812.72. The trade was a 31.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Julia Madsen sold 2,046 shares of the business’s stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $260.00, for a total transaction of $531,960.00. Following the completion of the sale, the vice president directly owned 10,211 shares of the company’s stock, valued at $2,654,860. This represents a 16.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 12,819 shares of company stock worth $3,274,011. Insiders own 1.12% of the company’s stock.
Institutional Investors Weigh In On STERIS
Several institutional investors and hedge funds have recently modified their holdings of the business. Advisors Asset Management Inc. bought a new stake in shares of STERIS during the 3rd quarter worth about $1,004,000. Innovator Capital Management LLC bought a new position in shares of STERIS in the 3rd quarter valued at approximately $1,138,000. Coastal Bridge Advisors LLC raised its stake in shares of STERIS by 29.1% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 3,196 shares of the medical equipment provider’s stock valued at $671,000 after acquiring an additional 721 shares in the last quarter. Integrated Wealth Concepts LLC lifted its holdings in STERIS by 16.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 3,664 shares of the medical equipment provider’s stock worth $769,000 after purchasing an additional 524 shares during the last quarter. Finally, Ancora Advisors LLC lifted its holdings in STERIS by 67.7% in the 3rd quarter. Ancora Advisors LLC now owns 2,831 shares of the medical equipment provider’s stock worth $595,000 after purchasing an additional 1,143 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.
STERIS Company Profile
STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.
Featured Stories
- Five stocks we like better than STERIS
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
